2026 H2 AbbVie China Partnering Day
In 2026, cross-border licensing transactions for innovative drugs in China continued to heat up, and multinational pharmaceutical companies accelerated their efforts to expand their local innovation in China. Recently, AbbVie, a global research-based…
Leaderna Therapeutics Completes Series A+ Financing to Advance Small Nucleic Acid Drug Pipeline
Chengdu-based Leaderna Therapeutics has completed a Series A+ financing round backed exclusively by Grand View Capital, adding fresh capital to accelerate clinical development of its small nucleic acid drug pipeline and further develop its extrahepatic…
Simnova Raises Nearly RMB 400 Million in Series B Financing to Advance CAR-NK and In Vivo CAR-T Platforms
Shanghai-based cell therapy developer Simnova has completed a nearly RMB 400 million (approximately US$55 million) Series B financing round, providing fresh capital to advance its lead off-the-shelf CAR-NK program SNC103 and its emerging in vivo CAR-T…
2026 Global XDC Innovation Conference
Explore the new frontiers of XDC fusion and breakthrough innovation – under the theme: Convergence & Innovation: The New Frontiers of Bioconjugation. Highlights Sneak Peek🔹 Focused Innovation Agenda – Key XDC technologies and emerging modalities,…
Ascletis Doses First Participant in Global Phase III Program of Oral GLP-1 Drug ASC30
Ascletis Pharma has dosed the first participant in its global Phase III AURORA clinical program evaluating ASC30, a once-daily oral small-molecule GLP-1 receptor agonist for chronic weight management, launching a roughly 4,600-patient registrational…
Chia Tai Tianqing Pharma (CTTQ)
Innovating for Life, Creating Greater Health Value
Kelun-Biotech Biopharma
Innovative ADCs and Drug Conjugates for Patients Worldwide
CStone Pharmaceuticals
Building Globally Competitive Innovative Medicines
Livzon/Kanova’s Lecankitug Gets China Approval After Beating Secukinumab in Phase 3 Psoriasis Trial
China’s National Medical Products Administration (NMPA) has approved lecankitug (LZM012/XKH004), an IL-17A/IL-17F-targeting monoclonal antibody jointly developed by Livzon Pharmaceutical Group and Beijing Kanova Biopharmaceutical, for the treatment of…
HUTCHMED’s Fanregratinib Wins China NMPA Approval for FGFR2+ Intrahepatic Cholangiocarcinoma (ICC)
HUTCHMED has secured conditional approval from China’s National Medical Products Administration (NMPA) for fanregratinib (HMPL-453), providing a new targeted treatment option for patients with FGFR2-altered intrahepatic cholangiocarcinoma (ICC). The NMPA…